By Stephen Nakrosis
GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule.
Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added.
In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years.
Vaccine doses will be ready for use in the U.S. in summer, GSK said.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
April 16, 2025 17:41 ET (21:41 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.